Swiss Medica - krass unterbewertet - Blockbuster bereits gelauncht - 500 Beiträge pro Seite

[Freddy11]

Kurs aktuell: 0,175 Dollar
Markkapitalsierung: 15,5 Mio Dollar
Handelbar: OTC

Quelle: DEL LA RUE - Investment Team

Swiss Medica Inc. erforscht, entwickelt und vermarktet Medikamente auf pflanzlicher Basis. Ende 2004 gelang es dem unternehmen mit dem Schmerzlindernden Medikament "O24" einen Blockbuster rauszubringen. Der Umsatz konnte seit der Vermarktung innerhalb von einem Jahr verdoppelt werden. Neben dem drittgrößten Drug-Store in den USA "Rite Aid" kann man "O24" inzwischen in über 1.600 Geschäften erwerben. Teilweise mussten sich Händler das Produkt für Monate im Voraus sichern um einen Engpass in der Belieferung zu vermeiden. SwissMedica geht daher davon aus noch in diesem Jahr schwarze Zahlen zu schreiben.

According to David A. Bench, editor of The Research Works, Inc., Swiss Medica’s stock is “significantly undervalued... We are convinced that encouraging clinical trials and positive ‘word of mouth’ should translate into robust revenue growth within the next few quarters.

[Freddy11]

On September 30th, Swiss Medica (OTC BB: SWME) was handed a godsend. Merck & Co announced a worldwide voluntary recall of its widely popular pain relief prescription medicine, Vioxx®. Swiss Medica scrambled to meet the avalanche of consumer demand for its all-natural O24™ topical pain reliever. Canada’s leading pharmacy chain quickly re-ordered after initial shipments were sold out. At the national AARP event in Las Vegas, seniors purchased up to several months supply of O24™ in case the product was not readily available to them in their neighborhood drugstore.
“Recent congressional hearings and FDA statements about the safety concerns of arthritis, and other pain, pills gave Swiss Medica a strong sales surge early in this quarter,” said CEO Raghu Kilambi. “The more educated, health-conscious consumer wants a pain-relief product without the dangerous side effects so he or she can remain active and robust.” Sales of O24™ have increased exponentially quarter to quarter over the past year, and are could double in Q4 over the previous quarter.

Swiss Medica is enjoying robust investor interest in its stock as a maturing US population eagerly searches for a safe alternative to pain pills. The O24™ pain relief product reportedly offers fast, long-lasting results from the pains associated with arthritis and backaches. The Gutman Back/Accident Center in Orlando (Florida) compared O24™ to Ben Gay®, Bio Freeze®, Tiger Balm® and other popular pain medications, including pain pills. The study found O24™ was 90 percent more effective than other pain relievers. Patients announced a pain reduction of 73 percent; 86 percent reported four or more hours of pain relief.
“It’s almost like a miraculous lotion,” said Dr. E. Michael Gutman, a double-board certified neuropsychiatric pain management specialist. “It has an effect of relief from pain for four to six hours. O24™ should be an integral part of everyone’s pain management strategy.”

O24™ Provides Chronic Pain Relief

O24™ is particularly effective in relieving pain associated with more than 100 types of arthritis, a condition that affects more than 42 million Americans each year. The Center for Disease Control (CDC) estimates there will be 60 million affected by the debilitating disease by 2020. Approximately 80 million Americans suffer from chronic pain from a variety of other causes, including backaches, musculoskeletal injuries, and fibromyalgia which affects muscles and fibrous tissues. According to Chain Drug Review, “Graying baby boomers contending with arthritis and weekend warriors suffering sprains and strains translate into big increases in the drug channel for a number of brands.”
Swiss Medica’s O24™ uniquely combines clinically tested ingredients, many used medicinally for centuries, into a US-patented blend. European medical studies suggest that because the essential oils, which comprise O24™, are 100-percent pure, the constituents in those oils are able to penetrate more deeply into the muscles, ligaments and joints to provide faster and longer-lasting relief than other products. The efficacy of O24™ has been broadly tested in European clinics and hospital emergency rooms. It is now undergoing an advanced clinical study in Toronto.
“O24™ has no binders, additives, preservatives or carriers that slow it down,” said Raghu Kilambi. Some topical pain relievers may contain mineral oils or paraffin that block the skin’s pores. Other pain relief products rely upon burning capsaicin (a skin irritant) or salicyclate. Scientist Richard Wiese, who invented the proprietary blending process, explained, “O24™ equalizes the affected body part’s temperature, returning the area to its normal temperature.”

North American Media Blitz Heralds O24™

Word of mouth about the O24™ pain reliever has been contagious. The pain relief product has been favorably reported upon on more than 100 US television stations, paving the way for its widespread national debut in US chain drugstores in 2005. Swiss Medica has created an enthusiastic demand at consumer, medical and investment trade shows. The company’s booth at the October 2004 AARP conference in Las Vegas is just one example of the success of Swiss Medica’s O24™ in the U.S. “This event confirmed everything that we believe about the product,” says Grant Johnson, president of Swiss Medica. “We were selling a bottle (of O24™) every three or four minutes.”
The list of testimonials grows longer every day as athletes and medical doctors agree there is something special about the O24™ topical pain reliever.

“You feel the sensations hours after you use it. It’s not like Ben Gay® or something like that you put on, where you get a little heat spell there, and about ten minutes later, everything is gone. O24™, you put it on, and it will be there for a few hours.” – Larry Holmes, former heavyweight boxing champion.
“By using O24™, we have been able to reduce the use of anti-inflammatory drugs normally used on the players for muscle and skeletal injuries.” – Chris Broadhurst, athletic trainer for the Toronto Maple Leafs hockey team.
“There are many topical pain relief products offered to consumers, but I believe O24™ is the one that medical and healthcare providers should be making available to their patients.” – Dr. Allan Fields, five-time ringside physician of the year and attending physician and surgeon at the Sinai Medical Center in Palm Beach, Florida.

Dr. Fields recently completed editing the new O24™ information guide to help educate physicians and other healthcare providers, the media and consumers about the broad benefits of this pain relief product. He has agreed to appear on national television and radio talk shows to discuss O24™ as the company’s medical spokesman.

Investment Considerations

Swiss Medica is led by a management team with more than 100 combined years of broad experience. In addition to O24™, new product lines are in development. The company’s business plan calls for a combined revenue stream from supermarket and drugstores (80%), convenience stores and sports/nutrition markets (15%), and direct sales to professional practices and the company’s online sales programs (5%).

The company is in advanced negotiations with major U.S. pharmacies and expects O24™ to be nationally distributed in the United States during the first half of 2005, according to Swiss Medica CEO Raghu Kilambi. In November, Swiss Medica announced its first US drugstore order, from a highly regarded and widely respected regional pharmacy chain.

Swiss Medica is looking beyond the US launch of its flagship O24™ product. “We plan to acquire other world-class chronic ailment products, specifically those which have been clinically tested and with existing traction in the marketplace,” said Executive Vice President Greg Nuttall.

In a recent investment bulletin alert, Jim Schusler of the Tampa-based Cornerstone Investment Group, which is associated with Florida’s largest investment club, announced that Swiss Medica is “a small cap company that is doing things like a Fortune 500 company.”

According to David A. Bench, editor of The Research Works, Inc., Swiss Medica’s stock is “significantly undervalued... We are convinced that encouraging clinical trials and positive ‘word of mouth’ should translate into robust revenue growth within the next few quarters.”

Note: Michael Reynolds, a paid public relations consultant for Swiss Medica, does not own stock in the company.

Quelle:The Bull & Bear Financial Reporter
www.thebullandbear.com/bb-reporter/bbfr-archive/swissmedica.html

[Freddy11]

Insider kaufen:

8/25/2005 12:50:33 PM ET News Release Index


SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN
FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME
Aug 25, 2005

SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN

TORONTO-Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that Swiss Medica’s senior management team and members of Swiss Medica’s Board of Directors intend to purchase on the open market, shares of the Company`s publicly traded Class A common stock, based on their assessment of prevailing market prices. Whether any such purchases are made, and the number of shares purchased, will depend upon the availability of shares at acceptable market prices. All trades will comply with Swiss Medica’s insider trading policy and insiders will file Form 4s with the S.E.C. as purchases are completed.

Mr. Raghu Kilambi, Swiss Medica’s CEO commented, “At current levels, we believe our stock is undervalued. These planned open market purchases illustrate our confidence in Swiss Medica’s underlying business strategy.”

[Freddy11]

Insider Buying Laut SEC Filings Form Nr. 4

Laut der SEC Filings Form Nr. 4 auf der Homepage von Swiss Medica Inc., wurden am 2. September insgesamt 50.000 Aktien zum Kurs von USD 0.2595 und 35.000 Aktien zum Kurs von USD 0.23 an Mitarbeiter verkauft!

Die ersten Transaktionen laut des Insider Buying Plan, wurden somit erstmals ausgeführt.

[Freddy11]

Swiss Medica Reports Early Success at Retail for PMS Escape

TORONTO--(BUSINESS WIRE)--Aug. 29, 2005--Swiss Medica, Inc. (OTCBB:SWME) today announced that just weeks after hitting U.S. retail shelves, its recently-launched PMS Escape product has been selling out in many stores.

"We are pleased to see such strong initial sales for PMS Escape," notes Wendy Kramer, Swiss Medica`s Vice President. "PMS Escape went into 5,000+ retail stores in late July and, in just two weeks, there have been reorders totaling more than 25% of the initial order. PMS is one of the most common women`s health problems in the U.S. and with PMS Escape, women now have a safe and clinically proven way to help them manage the mood and appetite symptoms associated with premenstrual syndrome," adds Kramer.

PMS Escape is a clinically tested, patented, all natural product to help women with premenstrual syndrome (PMS) related disturbances in mood and appetite. It is the first over the counter product available at retail to help women manage these disturbances. PMS Escape is a powdered drink mix that contains the precise amounts of carbohydrates, vitamins and minerals that work naturally with the body to raise serotonin levels, which scientists believe decrease during PMS. For retail availability, customers can go to www.pmsescape.com.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica`s mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com

Swiss Medica`s flagship product, the O24(TM) Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24(TM) pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24(TM) Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24(TM) Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia(TM) reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia(TM) and to order the product online.

Swiss Medica also manufactures PMS Escape(R) which holds US Patent #`s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica`s products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica`s periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica, Inc. (OTC Bulletin Board:SWME)

[Freddy11]

Walgreens Now Offering Swiss Medica`s O24 Pain Neutralizer
Tuesday September 20, 6:00 am ET


TORONTO--(BUSINESS WIRE)--Sept. 20, 2005--Swiss Medica, Inc. (OTC BB:SWME - News) is pleased to announce that Walgreens is now offering its O24 Pain Neutralizer product nationwide.
ADVERTISEMENT


"We are pleased that Walgreens has become the newest national pharmacy chain to carry O24 Pain Neutralizer," said Thomas Quinn, Swiss Medica`s Executive Vice President. "We believe this will enable millions of people who suffer daily pain to have access to our patented, effective and safe pain reliever."

[Freddy11]

Swiss Medica to Present to Institutional Investors in Europe
Tuesday October 4, 6:00 am ET

TORONTO--(BUSINESS WIRE)--Oct. 4, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) today announced that Chief Executive Officer, Raghu Kilambi will be making presentations to institutional investors on Swiss Medica and speaking at biotech investment conferences between October 4 and October 12th in Zurich, Cadaques (Spain), Paris, Brussels and London.

ADVERTISEMENT
Mr. Kilambi will present Swiss Medica on October 4-5th at the 5th Annual Biotech in Europe Investor Forum in Zurich, co-sponsored by Sachs Associates and Bloomberg LLP. In addition, Mr. Kilambi will present Swiss Medica on October 7-8th, 2005 at the invitation only Theime Small Cap Conference in Spain. The Thieme small cap conference showcases 6 carefully selected companies the Nanotechnology, Biotech and Energy fields.

Investors and analysts can view Swiss Medica`s latest corporate and investor brochure at www.swissmedica.com.

[Freddy11]

SWISS MEDICA INC filed this 8-K on 10/05/2005

On September 23, 2005, the Registrant issued 5,718,750 shares of its Class
A common stock in connection with the exercise of its outstanding Class C
Warrants. The Registrant received gross proceeds of $1,143,750 from the exercise
of such warrants. The Registrant also issued warrants to purchase 5,625,000
shares of its Class A common stock at $0.30 per share and expire on March 31,
2007. At October 5, 2005, the Registrant had 95,702,917 shares of Class A common
stock issued and outstanding. On a fully-diluted basis (i.e., counting all
warrants, options and convertible securities as if they had been exercised or
converted) the Company has 122,033,690 shares of Class A common stock
outstanding.

[Freddy11]

Meinungen?

[KlingerP]

Heute -8%.

Leider auf finance yahoo keine Daten zum finanziellen
Zustand der Firma erhältlich .
Wieviel Cash haben die, warum mussten die kürzlich Aktien Verkaufen (meldung vom 5.10.) etc? Umsatz ?

Es steht nur da, dass die Firma "commercializes" das Medikament .... wer kassiert die Tantiemen, wer hat es entwickelt?
Kann mir da kein richtiges Bild machen.



Charts:
http://finance.yahoo.com/q/bc?s=SWME.OB&t=3m





Insider verkauften vorwiegend. Käufe dagegen volumenmäßig
sehr bescheiden.
http://finance.yahoo.com/q/it?s=SWME.OB

16-Sep-05 STRATEGIC EQUITY CORP.
750,000 Direct Planned Sale $282,5001
2-Sep-05 FAIRBAIRN, BRUCE
Chief Financial Officer 35,000 Direct Private Purchase at $0.23 per share. $8,050
2-Sep-05 ORR, CHARLES E.
Director 50,000 Direct Purchase at $0.2595 per share. $12,975
1-Sep-05 OFFICE RADIO NETWORK INC
320,000 Direct Planned Sale $80,0001
12-Jul-05 SURGO, JULIUS C.
150,000 Direct Planned Sale $52,5001
31-May-05 HOLMES, LARRY
100,000 Direct Planned Sale $24,0001
23-May-05 KLEIN, ROBERT
Employee 200,000 Direct Planned Sale $50,0001
15-Apr-05 LANGLEY, RICK
585,136 Direct Planned Sale $172,6151
16-Mar-05 WASSON CAPITAL ADVISORY LTD
100,000 Direct Planned Sale $33,0001
8-Mar-05 LEE, JOHN
100,000 Direct Planned Sale $35,0001
8-Mar-05 HOLMES, PETER
100,000 Direct Planned Sale $35,0001
4-Mar-05 SAKRAIDA, MICHAEL G.
13,889 Direct Planned Sale $4,8611
4-Mar-05 MCDOWELL, JAMES E.
13,889 Direct Planned Sale $4,8611
1-Mar-05 RESEARCH WORKS INC
402,777 Direct Planned Sale $149,0271
19-Jan-05 WASSON CAPITAL ADVISORY LTD
553,515 Direct Planned Sale $232,4761
5-Jan-05 PERITUS CANADA INCORPORATED
525,000 Direct Planned Sale $170,6251
20-Sep-04 KLEIN, ROBERT
Employee 390,000 Direct Planned Sale $27,3001
22-Jun-04 WASSON CAPITAL ADVISORY LTD
553,515 Direct Planned Sale $88,5621
29-May-04 JONES, DAVID
385,000 Direct Planned Sale $119,3501
18-May-04 NUTTALL, GREG
Vice Chairman 534,451 Direct Planned Sale $133,0001
18-May-04 KLEIN, ROBERT
Employee 500,000 Direct Planned Sale $125,0001
19-Apr-04 NUTTALL, GREG
Vice Chairman 534,451 Direct Planned Sale $190,0001